These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10081301)

  • 1. [Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
    Scheen AJ
    Rev Med Liege; 1999 Jan; 54(1):2-3. PubMed ID: 10081301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [LIPID study [Long-term Intervention with Pravastatin in Ischaemic Disease study]].
    Homma Y
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():416-21. PubMed ID: 11347106
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
    N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
    Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
    Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
    Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
    Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
    J Atheroscler Thromb; 2000; 7(2):110-21. PubMed ID: 11426582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of the month. The ALLHAT-LLT trial].
    Kulbertus H; Scheen AJ
    Rev Med Liege; 2003 Jan; 58(1):53-8. PubMed ID: 12647600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
    J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
    Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pravastatin therapy and the risk of stroke.
    White HD; Simes RJ; Anderson NE; Hankey GJ; Watson JD; Hunt D; Colquhoun DM; Glasziou P; MacMahon S; Kirby AC; West MJ; Tonkin AM
    N Engl J Med; 2000 Aug; 343(5):317-26. PubMed ID: 10922421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
    Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.